home > news > detailed info

SEKISUI XenoTech Receives New US Patent for a Method to Evaluate Xenobiotics as Immune-Modulators of Drug Transport and Metabolism in Hepatocytes


Tuesday, May 12, 2020

Kansas City, KS- SEKISUI XenoTech has been awarded US patent # 10,648,968 “In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes.”

 In 2014, SEKISUI XenoTech patented an in vitro test system to evaluate whether an immuno-modulating drug can change expression of drug metabolizing enzymes in human hepatocytes and how it will interact with human hepatocytes. Xenobiotic metabolism is a core interest of SEKISUI XenoTech, and the company has now received this divisional patent to cover small molecule drugs in addition to the previously patented method that covered biologics or large molecule drugs.

Developed by Dr. Maciej Czerwinski, this in vitro process evaluates drug candidates for direct and cytokine-mediated effects on cytochrome P450 (CYP) enzyme expression. The original patent was for examination of biologic drugs and this divisional patent expands application of the invented test system for evaluation of small molecule drugs. First, the cytokine release assay examines the effects of the drug on the level of cytokines in the whole blood ex vivo. In the second step, effects of the cytokines on the expression of drug-metabolizing enzymes are evaluated in hepatocytes in vitro. Consideration is given to the appropriate drug concentration that will yield the most relevant data on the release of cytokines and their downstream impact. Our patented and novel approach yields cytokine release information and detects the direct and cytokine-mediated effects of small molecules on CYP and drug transporter expression.

Small molecule drugs still encompass the majority of compounds in development and increasingly these molecules are designed to modulate the immune system. Those that may be associated with the release of pro-inflammatory cytokines warrant evaluation before first in-human (FIH) clinical trials. Examination of cytokines stimulated by small molecule drugs is important since these signaling molecules can suppress drug-metabolizing enzymes. Cytokine-mediated suppression of drug metabolizing enzymes can change the clearance of concomitantly administered small molecule drugs and thereby precipitate a drug-drug interaction.

FDA recognizes the potential for drugs that are cytokines or cytokine modulators to change the plasma concentration of co-administered drugs. “It is crucial for developers and testing organizations to evolve and rise to meet new technological advances. As improvements are made in the way therapies are developed it is important to provide innovation and processes that match the needs of drug developers. SEKISUI XenoTech is committed to driving innovation as a means of supporting both safety assessment and effective pipeline development for our clients. We are also constantly adapting to stay abreast of the latest advances and provide expertise on the effects of drugs and the regulatory policies to protect potential patients. We are extremely proud of the work we do and the expanding expertise of our scientists,” stated VP of Scientific Consulting, Dr. Brian Ogilvie.

For more information regarding this newly patented and novel approach, please visit or contact SEKISUI XenoTech using the information below.
phone Phone: +1.913.438.7450 Toll-Free (North America): 1-877-588-7530
email 1101 West Cambridge Circle Dr. Kansas City, KS 66103
Print this page
Send to a friend
News and Press Releases

Murata’s RFID technology helps Bayer revolutionise transparency of its pharmaceutical supply chain

Hoofddorp, Netherlands: Murata ID Solutions has helped life science giant Bayer’s Italian division, Bayer S.p.A., leverage radio frequency identification (RFID) tracking in the first large-scale application of the technology in the pharmaceutical supply chain. The pioneering project has enabled Bayer to gain real-time visibility over its distribution processes to optimise customer service, improve product security and asset tracking, and enhance response to unprecedented threats.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis


There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement